Related Experiment Video
Updated: Aug 24, 2026

Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
In vivo role of heme oxygenase in ischemic coronary vasodilation
Yasuhiro Nishikawa1, David W Stepp, Daphne Merkus
1Department of Physiology, Medical College of Wisconsin, Watertown, WI 53226, USA.
Insights
The heme oxygenase-carbon monoxide (HO-CO) pathway in the heart causes vasodilation during ischemia. This pathway plays a backup role, activating when other mechanisms are exhausted, and involves cGMP-mediated relaxation.
Area of Science:
- Cardiovascular Physiology
- Molecular Cardiology
- Ischemic Pathophysiology
Background:
- The heart expresses heme oxygenase-2 (HO-2), which metabolizes heme to produce carbon monoxide (CO).
- Carbon monoxide (CO) is known to activate guanylyl cyclase, leading to vascular relaxation.
- Heme oxygenase (HO) activity has been linked to protection against ischemic injury.
Purpose of the Study:
- To investigate the role of the HO-CO pathway in mediating vasodilation within the coronary microcirculation during myocardial ischemia.
- To determine if HO-2 activation contributes to ischemic vasodilation and if this mechanism is cGMP-dependent.
Main Methods:
- Epicardial coronary arterioles' responses to ischemia were measured using stroboscopic fluorescence microangiography in anesthetized dogs.
- The study employed antagonists for nitric oxide (L-NMMA), prostaglandins (indomethacin), and hyperpolarizing factors (K+).
- Heme oxygenase (HO) inhibition was achieved using tin mesoporphyrin IX (SnMP), and guanylyl cyclase inhibition used 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one.
Main Results:
- Ischemia induced significant vasodilation in coronary arterioles.
- Inhibition of nitric oxide, prostaglandins, and hyperpolarizing factors partially reduced this dilation.
- The remaining vasodilation was significantly inhibited by tin mesoporphyrin IX (HO inhibitor) and the guanylyl cyclase inhibitor, indicating a role for the HO-CO pathway.
Conclusions:
- Heme oxygenase-2 (HO-2) activation during myocardial ischemia leads to cGMP-mediated vasodilation, likely through carbon monoxide (CO) production.
- This HO-CO pathway serves as a backup mechanism for vasodilation during ischemia.
- The pathway is activated only after other vasodilatory mechanisms are significantly impaired or exhausted.
Abstract:
The heart constitutively expresses heme oxygenase (HO)-2, which catabolizes heme-containing proteins to produce biliverdin and carbon monoxide (CO). The heart also contains many possible substrates for HO-2 such as heme groups of myoglobin and cytochrome P-450s, which potentially could be metabolized into CO. As a result of observations that CO activates guanylyl cyclase and induces vascular relaxation and that HO appears to confer protection from ischemic injury, we hypothesized that the HO-CO pathway is involved in ischemic vasodilation in the coronary microcirculation. Responses of epicardial coronary arterioles to ischemia (perfusion pressure approximately 40 mmHg; flow velocity decreased by approximately 50%; dL/dt reduced by approximately 60%) were measured using stroboscopic fluorescence microangiography in 34 open-chest anesthetized dogs. Ischemia caused vasodilation of coronary arterioles by 36 +/- 6%. Administration of N(G)-monomethyl-L-arginine (L-NMMA, 3 micromol.kg(-1).min(-1) intracoronary), indomethacin (10 mg/kg iv), and K(+) (60 mM, epicardial suffusion) to prevent the actions of nitric oxide, prostaglandins, and hyperpolarizing factors, respectively, partially inhibited dilation during ischemia (36 +/- 6 vs. 15 +/- 4%; P < 0.05). The residual vasodilation during ischemia after antagonist administration was inhibited by tin mesoporphyrin IX (SnMP, 10 mg/kg iv), which is an inhibitor of HO (15 +/- 4 vs. 7 +/- 2%; P < 0.05 vs. before SnMP). The guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (10(-5) M, epicardial suffusion) also inhibited vasodilation during ischemia in the presence of L-NMMA with indomethacin and KCl. Moreover, administration of heme-L-arginate, which is a substrate for HO, produced dilation after ischemia but not after control conditions. We conclude that during myocardial ischemia, HO-2 activation can produce cGMP-mediated vasodilation presumably via the production of CO. This vasodilatory pathway appears to play a backup role and is activated only when other mechanisms of vasodilation during ischemia are exhausted.
Related Concept Videos
Oxygen Transport in the Blood
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Nitric Oxide Signaling Pathway
Autoregulation of Blood Flow
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation.
Coronary Artery Disease II: Pathophysiology
Hypoxia
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...

